Teva Pharmaceuticals has announced an innovation in the way of drug metabolizing. To prolong therapy digestion and ensure drug abilities, Teva has begun replacing various hydrogen atoms within a drug with isotope deuterium. This heavier element, when introduced to a drug’s composition, allows the drug to remain unchanged for longer within the human body, increasing chances of therapy success. The isotope, commonly referred to a “heavier hydrogen,” increases the drug’s atomic weight which makes acidic breakdown more difficult. This has been primarily used in Teva’s Huntington disease therapy. Read the full article here.